Long-term safety and effectiveness of linagliptin by baseline body mass index in Japanese patients with type 2 diabetes: a 3-year post-marketing surveillance study-Reference-Cited by-同舟云学术

Long-term safety and effectiveness of linagliptin by baseline body mass index in Japanese patients with type 2 diabetes: a 3-year post-marketing surveillance study

Published:2022-05-03 Issue:10 Volume:21 Page:1303-1313
ISSN:1474-0338
Container-title:Expert Opinion on Drug Safety
language:en
Short-container-title:Expert Opinion on Drug Safety

Author:

Yabe Daisuke¹²³⁴^ORCID,Yamamoto Fumiko⁵,Lund Søren S.⁶,Okamura Tomoo⁵,Kadowaki Takashi⁷

Affiliation:

1. Department of Diabetes, Endocrinology and Metabolism and Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Gifu, Japan

2. Yutaka Seino Distinguished Center for Diabetes Research, Kansai Electric Power Medical Research Institute, Kobe, Japan

3. Division of Molecular and Metabolic Medicine, Kobe University Graduate School of Medicine, Kobe, Japan

4. Center for Healthcare Information Technology, Tokai National Higher Education and Research System, Nagoya, Japan

5. Nippon Boehringer Ingelheim Co., Ltd, Tokyo, Japan

6. Boehringer Ingelheim International GmbH, Ingelheim, Germany

7. President, Toranomon Hospital, Tokyo, Japan

Funder

Nippon Boehringer Ingelheim Co. Ltd

Publisher

Informa UK Limited

Subject

Pharmacology (medical),General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14740338.2022.2057948

Reference21 articles.

1. International Diabetes Federation. IDF diabetes atlas. Belgium: International Diabetes Federation; 2019. [cited 2022 Apr 5]. Available from: https://www.diabetesatlas.org/en/resources/.

2. Ministry of Health, Labour, and Welfare, Japan. National Health and Nutrition Survey. 2016. [cited 2022 Apr 5]. Available from: https://www.mhlw.go.jp/english/

3. Japanese Clinical Practice Guideline for Diabetes 2019

4. Real-world Observational Study on Patient Outcomes in Diabetes (RESPOND): study design and baseline characteristics of patients with type 2 diabetes newly initiating oral antidiabetic drug monotherapy in Japan

5. Linagliptin